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Summary
Background Many patients with primary biliary cholangitis have an inadequate response to first-line therapy with 
ursodeoxycholic acid. Seladelpar is a potent, selective agonist for the peroxisome proliferator-activated receptor-delta 
(PPAR-δ), which is implicated in bile acid homoeostasis. This first-in-class study evaluated the anti-cholestatic effects 
and safety of seladelpar in patients with an inadequate response to ursodeoxycholic acid.
Methods The study was a 12-week, double-blind, placebo-controlled, phase 2 trial of patients with alkaline phosphatase 
of at least 1·67 times the upper limit of normal (ULN) despite treatment with ursodeoxycholic acid. Patients, recruited 
at 29 sites in North America and Europe, were randomly assigned to placebo, seladelpar 50 mg/day, or seladelpar 
200 mg/day while ursodeoxycholic acid was continued. Randomisation was done centrally (1:1:1) by a computerised 
system using an interactive voice–web response system with a block size of three. Randomisation was stratified by 
region (North America and Europe). The primary outcome was the percentage change from baseline in alkaline 
phosphatase over 12 weeks, analysed in the modified intention-to-treat (ITT) population (any randomised patient who 
received at least one dose of medication and had at least one post-baseline alkaline phosphatase evaluation). This 
study is registered with ClinicalTrials.gov (NCT02609048) and the EU Clinical Trials Registry (EudraCT2015-002698-39).
Findings Between Nov 4, 2015, and May 26, 2016, 70 patients were screened at 30 sites in North America and Europe. 
During recruitment, three patients treated with seladelpar developed fully reversible, asymptomatic grade 3 alanine 
aminotransferase increases (one on 50 mg, two on 200 mg), ranging from just over five to 20 times the ULN; as a 
result, the study was terminated after 41 patients were randomly assigned. The modified ITT population consisted of 
12 patients in the placebo group, 13 in the seladelpar 50 mg group, and 10 in the seladelpar 200 mg group. Mean 
changes from baseline in alkaline phosphatase were –2% (SD 16) in the placebo group, –53% (14) in the seladelpar 
50 mg group, and –63% (8) in the seladelpar 200 mg group. Changes in both seladelpar groups versus placebo were 
significant (p<0.0001 for both groups vs placebo), with no significant difference between the two seladelpar groups 
(p=0·1729). All five patients who received seladelpar for 12 weeks had normal alkaline phosphatase values at the end 
of treatment, based on a central laboratory ULN for alkaline phosphatase of 116 U/L. The most frequently reported 
adverse events were pruritus (16%; one patient on placebo, four on seladelpar 50 mg, and one on seladelpar 200 mg), 
nausea (13%; one patient on placebo, three on seladelpar 50 mg, and one on seladelpar 200 mg), diarrhoea (10%; two 
patients on placebo, one on seladelpar 50 mg, and one on seladelpar 200 mg), dyspepsia (8%; two patients on 
seladelpar 50 mg and one on seladelpar 200 mg), muscle spasms (8%; three patients on seladelpar 200 mg), myalgia 
(8%; one patient on placebo and two on seladelpar 200 mg), and dizziness (8%; one patient on placebo and two on 
seladelpar 50 mg).
Interpretation Seladelpar normalised alkaline phosphatase levels in patients who completed 12 weeks of treatment. 
However, treatment was associated with grade 3 increases in aminotransferases and the study was stopped early. The 
effects of seladelpar should be explored at lower doses.
Funding CymaBay Therapeutics.
Introduction
Primary biliary cholangitis, formerly known as primary 
biliary cirrhosis, is a chronic, progressive, cholestatic liver 
disease.1 The liver shows a lymphocytic infiltration with 
progressive damage to lobular bile ducts, which leads to 
impaired bile flow. Although the condition is presumed to 
have an autoimmune aetiology, chronic cholestasis drives 
the pathophysiological process, and can lead to cirrhosis. 
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Primary biliary cholangitis occurs predominantly in 
women and is often first suspected by persistent elevations 
of serum alkaline phosphatase on routine blood tests. 
Patients progress at varying rates, although a diagnosis at 
a younger age appears to negatively affect prognosis.2 
Inadequate medical treatment puts patients at risk of liver 
death and the need for liver transplantation. Two drugs, 
ursodeoxycholic acid and obeticholic acid, have been 
approved to medically treat primary biliary cholangitis.3,4
Ursodeoxycholic acid, a non-cytotoxic bile acid, has been 
the mainstay of therapy for more than 20 years.1,5 However, 
up to 40% of patients have persistent elevation of alkaline 
phosphatase or bilirubin or both despite treatment with 
ursodeoxycholic acid and are considered inadequate 
responders.6 These patients have a worse hepatic transplant-
free survival rate compared with ursodeoxycholic acid 
responders.7,8 Consequently, alkaline phosphatase, when 
combined with total bilirubin, are now considered 
surrogate markers of primary biliary cholangitis severity 
that predict the progression of the disease.9
Obeticholic acid, a synthetic analogue of cheno-
deoxycholic acid, was recently conditionally ap proved 
based on its ability to decrease alkaline phosphatase 
concentrations when used as an add-on therapy in 
patients with primary biliary cholangitis who are 
inadequate responders to ursodeoxycholic acid. It is also 
approved for patients who cannot tolerate ursodeoxycholic 
acid (around 5% of patients). By contrast with 
ursodeoxycholic acid, obeticholic acid activates the 
farnesoid X receptor10 and exerts its effects through a 
distinct mechanism of action. However, about 50% of 
patients with primary biliary cholangitis still lack an 
adequate response to a combination of ursodeoxycholic 
acid and obeticholic acid.4 Also, obeticholic acid has been 
associated with inducing or worsening pruritus, a 
characteristic symptom of primary biliary cholangitis, 
which can require treatment interruption.4 Accordingly, 
there is still a substantial medical need to develop new 
therapies for primary biliary cholangitis.11
Peroxisome proliferator-activated receptors (PPARs) are 
nuclear receptors that direct the transcription of genes 
involved in bile acids or sterols, lipids, and glucose 
metabolism, as well as inflammation.12–14 Three PPAR 
subtypes—α, γ, and δ—are known,13 each of which have 
Research in context
Evidence before this study
Primary biliary cholangitis is a progressive cholangitic liver 
disease which, if untreated, progresses to cirrhosis and death or 
liver transplantation. We searched PubMed with no language 
limitations using the terms “primary biliary cirrhosis”, “primary 
biliary cholangitis”, “liver cirrhosis, biliary”, “trial”, “drug”, 
and “therapy”. We also searched the ClinicalTrials.gov database 
for clinical trials in primary biliary cirrhosis or primary biliary 
cholangitis. Both searches were censored on April 20, 2017. In 
primary biliary cholangitis, the standard of care for over 
20 years has been the hydrophilic bile acid ursodeoxycholic acid. 
The response to ursodeoxycholic acid is variable, with a 
substantial proportion of patients (up to 40%) having an 
inadequate response in terms of liver biochemistry 
improvement and reduced survival. Non-response to 
ursodeoxycholic acid is more frequent in younger patients, 
increasing the level of unmet need in primary biliary 
cholangitis. Appreciation of the need for better therapy in 
patients with high-risk primary biliary cholangitis led to the 
development of the second-line therapy, obeticholic acid, which 
was approved for use in both the USA and Europe in 2016 in 
patients showing an inadequate response to ursodeoxycholic 
acid. Obeticholic acid (a synthetic bile acid) acts via agonism of 
the farnesoid X receptor, which regulates bile acid 
homoeostasis. However, obeticholic acid has two important 
limitations as second-line therapy. The first is that it is itself 
incompletely effective, with 50% of high-risk patients treated 
with it showing inadequate response in a phase 3 trial. The 
second is that it can cause worsening of pruritus (a key 
symptom of primary biliary cholangitis) and induce pruritus in 
previously symptom-free patients. Given the association 
between disease (and thus the need for obeticholic acid) and 
pruritus, this represents an important potential limitation in its 
use. With these limitations, the search for additional and 
alternative second-line therapies is ongoing.
Added value of this study
This study is a first-in-class, randomised, placebo-controlled 
trial of a PPAR-δ agonist in primary biliary cholangitis. 
The mode of action of the drug on bile acid synthesis and 
inflammation, and its non-bile-acid-based structure make it an 
intuitive agent to explore as second-line therapy in primary 
biliary cholangitis. The trial had two important positive findings 
and one caution. The positive finding, albeit based on a limited 
number of patients, is a normalisation of liver biochemistry in 
patients reaching 12 weeks of therapy. Improvement was also 
seen in other cholestatic markers suggesting a true 
anti-cholestatic effect and the mechanism of action appeared 
to be through reduced bile acid synthesis as predicted. 
The second positive finding was that there was no evidence of 
pruritus as a side-effect. However, a note of caution should be 
made since three patients showed rapidly reversible alanine 
aminotransferase (ALT) elevations.
Implications of all the available evidence
Seladelpar has the potential to be an improved second-line 
therapy in high-risk primary biliary cholangitis. A study at lower 
doses is underway to identify effective doses that do not cause 
ALT elevation (NCT029556020 and EudraCT 2016-002996-91). 
If the risk of ALT elevation can be eliminated while retaining 
efficacy, the drug offers the potential for routine liver 
biochemistry normalisation in high-risk patients with primary 
biliary cholangitis.
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their own distinct but overlapping cellular expression, 
target genes, pathway regulation, and biological functions. 
Fenofibrate, a PPAR-α agonist,15 and bezafibrate, a pan-
PPAR agonist,16 have shown promising activity in 
decreasing markers of cholestasis in patients with 
primary biliary cholangitis, although there are concerns 
about potential toxic effects. Their primary effects result 
from decreasing hepatocellular bile acid concentrations 
by regulation of genes responsible for bile acid synthesis 
and transport.17,18 Seladelpar (MBX-8025) is an oral, once-
daily, potent, and selective PPAR-δ agonist.12 Like PPAR-α, 
PPAR-δ is also expressed in hepatocytes,19 where it 
controls genes involved in bile acid homoeostasis. 
Seladelpar downregulates the expression of cyp7a1 which 
encodes cholesterol 7α-hydroxylase (appendix p 10), the 
enzyme that hydroxylates cholesterol in the first step in 
the synthesis of bile acids. Unlike PPAR-α, for which liver 
expression is mainly restricted to hepatocytes,20 PPAR-δ is 
also expressed in cholangiocytes,21 Kupffer cells, and 
hepatic stellate cells,19 and its activation in these cells has 
implications for modifying progression of primary biliary 
cholangitis. Cholangiocytes use PPAR-δ21 to regulate 
transporters involved in the absorption and secretion of 
bile components. Seladelpar regulates the cholesterol 
transporter ABCG5/ABCG8 in mouse liver (appendix 
p 11) and another PPAR-δ agonist was shown to increase 
bile flow three-fold in mice.22 Activation of PPAR-δ also 
results in anti-inflammatory effects in macrophages,23 
including Kupffer cells.24 Seladelpar, in a mouse model, 
reduces markers of liver inflammation, including 
reductions in macrophage numbers, re ductions in 
fibrosis, and reduction of other markers of stellate cell 
activity.25 Thus, the rationale for assessing PPAR-δ as a 
target for cholestatic diseases includes the impact on bile 
acid retention, cholangiocyte function, and anti-
inflammatory and anti-fibrotic effects on Kupffer and 
stellate cells.
Although primary biliary cholangitis is an autoimmune 
disease, the ensuing cycle of biliary epithelial injury, 
cholestasis, and fibrosis is thought to be substantially 
more important as a determinant of outcome for patients, 
with multiple strands of evidence supporting the 
importance of biliary epithelial responses to injury in 
driving the clinical course. The effects on cholestasis, 
inflammation, and fibrosis resulting from PPAR-δ 
agonism are therefore predicted to affect disease 
progression. In healthy volunteers, seladelpar decreased 
the intestinal absorption of cholesterol, decreased the 
synthesis of cholesterol, and modulated bile acid 
synthesis.26 In patients with mixed dyslipidaemia12 or 
homozygous familial hypercholesterolaemia,27 seladelpar 
reduced low-density lipoprotein cholesterol (LDL-C) and 
also induced sustained decreases in biochemical markers 
of cholestasis, such as alkaline phosphatase, γ-glutamyl 
transpeptidase (GGT), and total bilirubin.27 Seladelpar 
treatment also decreased biochemical markers of 
inflammation,12 an activity that could be of benefit to treat 
autoimmune diseases such as primary biliary cholangitis. 
So far, about 140 patients have received seladelpar at 
doses ranging from 50 mg/day to 200 mg/day for up to 
12 weeks.12,26,27 Seladelpar appeared safe and well tolerated 
with no specific adverse reaction definitively associated 
with the drug.12,26,27 Seladelpar was not associated with 
drug-induced pruritus.12,26,27
The aim of the present study was to explore the 
efficacy and safety of seladelpar in patients with primary 
biliary cholangitis who are inadequate responders to 
ursodeoxycholic acid treatment.
Methods
Study design and participants
This study was an international, multicentre, double-blind, 
randomised, placebo-controlled, parallel, dose-ranging 
trial of 18 weeks’ duration. All patients were to continue 
their ursodeoxycholic acid treatment at the same dose 
during the study. After signing informed consent, patients 
underwent a 4-week screening period to confirm eligibility.
The study enrolled patients aged 18–75 years with a 
diagnosis of primary biliary cholangitis at 29 centres in 
North America and Europe. The diagnosis required the 
presence of at least two of the following criteria: a history 
of alkaline phosphatase above the upper limit of normal 
(ULN) for at least 6 months, a positive autoantibody test 
(anti-mitochondrial antibody >1:40 on 
immunofluorescence or M2 positivity by enzyme-linked 
immunosorbent assay or positive anti-nuclear antibodies 
specific to primary biliary cholangitis), and a documented 
liver biopsy consistent with primary biliary cholangitis. 
Patients were required to be on a stable and recommended 
dose of ursodeoxycholic acid for the past 12 months and 
to have an alkaline phosphatase of at least 1·67 times 
the ULN.
Patients were excluded if they had any other liver 
conditions, or any medical condition that would preclude 
full participation, confound the results, or compromise 
their safety. Other exclusions were alanine 
aminotransferase (ALT) or aspartate aminotransferase 
(AST) concentrations more than three times the ULN, 
total bilirubin more than two times the ULN, and creatine 
kinase or serum creatinine above the ULN. The use of 
colchicine, methotrexate, azathioprine, or systemic 
steroids within 2 months before screening was not 
permitted. Patients taking fibrates or simvastatin were 
also excluded, as well as any patients on experimental 
primary biliary cholangitis treatment, including 
obeticholic acid. For patients of reproductive age, 
appropriate methods of contraception were to be used.
The study was approved by the relevant health 
authorities of the participating countries (Canada, 
Germany, Poland, the UK, and the USA) and independent 
ethics committees. The study was monitored by an 
independent data and safety monitoring board. [A: 
additon OK?] All patients provided written informed 
consent to participate. The study was done in accordance 
See Online for appendix
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with the principles of The Declaration of Helsinki and 
Good Clinical Practice Guidelines.
Randomisation and masking
Eligible patients were randomly assigned (1:1:1) after the 
4-week screening period to placebo, seladelpar 50 mg, or 
seladelpar 200 mg orally once daily using a centralised 
online response system (interactive web response system) 
and entered the double-blind 12-week treatment period. 
The randomisation was stratified by region (North 
America and Europe) and used a block size of three. A 
third-party vendor (Perceptive Informatics, Waltham, MA, 
USA) was responsible for generating the randomisation 
scheme and managing randomisation activities. Each 
patient was assigned a unique study identification number 
by the interactive web response system, and this triggered 
masked, patient-specific, on-demand shipment of the 
study drug. To maintain masking, all study medication 
capsules were identical in appearance.  Patients, 
investigators, clinical trial site staff, and sponsor staff 
directly involved with the study were masked to treatment 
assignment throughout the study. Masking of medication 
was completed by the masking of alkaline phosphatase 
values. GGT, ALT, and AST values, which were necessary 
for safety monitoring, were not masked.
Procedures
During treatment, site visits occurred at weeks 2, 4, 8, 
and 12, and telephone contact was made at weeks 6 
and 10. A follow-up assessment took place 2 weeks after 
the end of treatment.
Participants with creatine kinase of more than five 
times the ULN and musculoskeletal symptoms were 
discontinued from the study drug and withdrawn from 
the study; those with creatine kinase of more than five 
times the ULN without musculoskeletal symptoms were 
to be retested within 48 h, and if creatine kinase was still 
above the ULN, patients were to discontinue study drug 
and were withdrawn from the study. Patients were also to 
discontinue the study drug in the event of hepatic 
decompensation. For individuals with creatine kinase 
above 2·5 times but less than five times the ULN with 
musculoskeletal symptoms, the study drug was to be 
interrupted until resolution, at which point the drug 
could be resumed at a lower dose. Patients with creatine 
kinase above 2·5 times but less than five times the ULN 
without musculoskeletal symptoms were to be retested 
within 72 h, and if still raised, the study drug was to be 
continued at a lower dose.
Safety was assessed throughout the study by physical 
examination, ECG, the monitoring of adverse events and 
treatment-emergent adverse events, the recording of 
concomitant medications, and laboratory assessments. 
The severity of adverse events and laboratory ab normal-
ities were graded as per the Common Terminology 
Criteria for Adverse Events (version 4.03). The data and 
safety monitoring board periodically reviewed safety data 
[A: edit OK?]. A central laboratory did haematological 
and biochemical determinations (Medpace Reference 
Laboratories; Cincinnati, OH, USA, and Leuven, 
Belgium). Seladelpar and its metabolites were analysed by 
MicroConstants (San Diego, CA, USA).
Outcomes
The primary efficacy assessment was change from 
baseline in alkaline phosphatase concentrations over 12 
weeks. Secondary assessments were tolerability and 
safety and additional efficacy parameters. Secondary 
efficacy assessments included a composite of an alkaline 
phosphatase value less than 1·67 times the ULN with 
normal total bilirubin and a decrease of at least 15% from 
baseline; an evaluation of published primary biliary 
cholangitis response criteria (Paris I and II, Toronto I 
and II, and the UK primary biliary cholangitis risk score); 
AST, ALT, GGT, 5ʹ-nucleotidase, bilirubin (total, 
conjugated, and unconjugated), bone-specific alkaline 
phosphatase, triglycerides, total cholesterol, high-density 
lipoprotein cholesterol (HDL-C), and LDL-C; and pruritus 
evaluated with a visual analogue score, the 5D-itch 
questionnaire, and the PBC-40 quality-of-life questionnaire.
Exploratory efficacy measures included serum or 
plasma concentrations of the following: bile acid 
pre cursor 7α-hydroxy-4-cholesten-3-one (C4); high-
sensitivity C-reactive protein (hs-CRP); bile acids 
(ursodeoxycholic acid, cholic acid, chenodeoxycholic 
acid, deoxycholic acid, and lithocholic acid, their glyco-
conjugates and tauro-conjugates); IgM, anti-mito-
chondrial antibody, and homocysteine; 7α-hydroxy 
cholesterol; inter mediates of cholesterol synthesis 
(squalene, lanosterol, desmosterol, lathosterol, and 
7-dehydrocholesterol); markers of intestinal cholesterol 
absorp tion (β-sitosterol, campesterol, and stigmasterol); 
and cholestanol and coprostanol. In selected centres, 
shear wave elastography of the liver was done but the 
results are not reported here. Concentrations of 
fibroblast-growth factor 19 (FGF-19), an enterokine 
released after farnesoid X receptor activation, were 
measured post hoc. Trough plasma concentrations of 
seladelpar and its metabolites (M1, M2, and M3) were 
measured at weeks 4 and 12.
Statistical analysis
The safety analysis was done on the safety population, 
which included any randomised patient who received at 
least one dose of medication. Efficacy analyses were done 
on the modified intention-to-treat (mITT) population, 
which consisted of any randomised patient who received at 
least one dose of medication and had at least one post-
baseline alkaline phosphatase evaluation. It was assumed 
that the mean percent alkaline phosphatase decrease 
would not be more than 5% in the placebo group and at 
least 25% in the seladelpar groups with an SD for the 
percent change from baseline to end of treatment of 20%. 
Based on these assumptions, using a two-sided comparison 
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of means at the alpha 0·05 level of significance with a 
sample size of 23 patients per group, the study had a 90% 
power to detect a difference of 20% between the active and 
placebo groups. To account for up to two patients per 
group who might be excluded from the mITT population, 
the planned sample size was 25 patients per group. 
Baseline was defined as the mean between screening 
and baseline (day 1) values for the primary analysis and 
day 1 as baseline values for other analyses.
Descriptive statistics (ie, means, medians, and 
measures of dispersion) were to be presented and the last 
observation carried forward method was used for missing 
laboratory data. The primary efficacy analysis compared 
the mean percentage change in alkaline phosphatase 
concentrations from baseline to end of treatment between 
the seladelpar 200 mg treatment group and the placebo 
group. If this analysis was significant, the next comparison 
was between the seladelpar 50 mg treatment group and 
the placebo group. For the primary analysis, one-way 
ANOVA was used. A similar analysis was used for 
secondary analyses on normally distributed parameters. 
In the absence of normality, a non-parametric test was 
used (Wilcoxon). Statistical analyses were done using 
SAS version 9.4. This study is registered with CinicalTrials.
gov (NCT02609048) and the EU Clinical Trials Registry 
(EudraCT2015-002698-39).
Role of the funding source
CymaBay Therapeutics funded the study and supported 
the study design, data collection, analysis, and operation 
of the study. All authors had access to the datasets and 
statistical analysis plan and had rights to audit data. DJ, 
PFB, MGS, CLB, and GMH finalised data presentation 
and had responsibility to submit the manuscript after
obtaining agreement from all the authors.
Results
Between Nov 4, 2015, and May 26, 2016, 70 patients 
were screened. While recruitment was still ongoing, 
three patients on masked treatment developed grade 3 
aminotransferase elevations (ranging from just over 
five to 20 times the ULN; appendix p 13). All three cases 
were deemed to be drug related. Consequently, on 
May 27, 2016, the funder terminated the study and 
informed study sites, the data and safety monitoring 
board, and health authorities of its decision. Patients 
were requested to discontinue their treatment, return 
to study sites to complete an end-of-treatment visit, and 
then proceed to a follow-up (off-treatment) end-of-study 
visit 2 weeks later. As a result, only 41 patients were 
randomly assigned to a treatment group (figure 1). 
Two patients did not receive treatment because the 
study was discontinued after randomisation but before 
dosing, and one patient developed a variceal bleed after 
r a n d o m i s a t i o n 
but before dosing. The remaining 38 patients who 
received either placebo or seladelpar constituted the 
safety population. Mean age was 55 years [A: should 
this be median, as in table 1? Please add IQR  or SD] 
and most patients were women (table 1). There was an 
Figure 1: Trial profile
mITT=modified intention to treat.
13 patients allocated to seladelpar 200 mg
12 in the safety population
10 in the mITT population
2 did not have a post-baseline alkaline
phosphatase assessment
2 completed treatment
10 discontinued
6 study termination
3 due to adverse event
1 withdrew consent
14 patients allocated to seladelpar 50 mg
41 randomly assigned
29 failed screening
70 patients screened
13 in the safety population
13 in the mITT population
3 completed treatment
10 discontinued
9 study termination
1 due to adverse event
14 patients allocated to placebo
13 in the safety population
12 in the mITT population
1 did not have a post-baseline alkaline
phosphatase assessment
4 completed treatment
9 discontinued
9 study termination
1 not treated 1 not treated 1 not treated
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imbalance in baseline alkaline phosphatase and GGT 
concentrations among groups (table 1). Other baseline 
characteristics were well balanced.
15 patients completed 8 weeks of treatment (six on 
placebo, five on seladelpar 50 mg, and four on seladelpar 
200 mg) and nine patients completed 12 weeks of 
treatment (four on placebo, three on seladelpar 50 mg, 
and two on seladelpar 200 mg; table 2).
Alkaline phosphatase changes from baseline over 
12 weeks are presented in figure 2. Mean change from 
baseline in the placebo group was –2% (SD 16). The 
mean percentage change in alkaline phosphatase in 
both seladelpar groups was significant compared with 
placebo, with a decrease from baseline of 53% (SD 14) in 
the 50 mg group and a decrease from baseline of 63% 
(8) in the 200 mg group (both p<0·0001 vs placebo). 
There were no clinically relevant or statistically 
significant differences between the seladelpar groups 
(p=0·1167). Over 12 weeks, patients on both doses of 
seladelpar had a rapid decrease in alkaline phosphatase, 
whereas patients on placebo had stable alkaline 
phosphatase concentrations (figure 3). Decreases in 
alkaline phosphatase were recorded after 2 weeks of 
treatment, the first assessment in the study, with a 
slower decline up to week 12. All five patients on 
seladelpar who reached 12 weeks on treatment had 
normal alkaline phosphatase concentrations by week 12, 
based on a central laboratory ULN for alkaline 
phosphatase of 116 U/L (table 2). No patient on placebo 
had normal alkaline phosphatase levels after 12 weeks. 
As early as 8 weeks, eight (89%) of nine patients on 
seladelpar had normal alkaline phosphatase values. For 
the composite outcome of alkaline phosphatase and 
total bilirubin, at 12 weeks, all patients on seladelpar 
and none on placebo were responders (table 2).
Decreases were also noted with seladelpar in the 
concentrations of other cholestasis-associated enzymes, 
GGT, and 5ʹ-nucleotidase (appendix p 1). There were no 
significant differences in the GGT or 5ʹ-nucleotidase 
changes between the seladelpar groups. The mean 
percentage changes in total bilirubin, indirect bilirubin, 
and direct bilirubin are shown in the appendix (p 1). 
Significant decreases in hs-CRP and in LDL-C were 
recorded for both seladelpar groups compared with 
placebo (appendix p 1). The mean percentage changes in 
HDL-C and triglycerides are also presented in the 
appendix (p 1).
Over 12 weeks, there were significant decreases in C4, 
a marker of de-novo bile acid synthesis, in both seladelpar 
groups (figure 4), with no significant difference between 
seladelpar groups. The decreases in C4 were accompanied 
by decreases in 7-α-hydroxy-cholesterol, the precursor of 
C4 (appendix p 2). The median percentage changes in 
bile acid concentrations are shown in the appendix 
(pp 2, 3). Median percentage changes in lathosterol, 
β-sitosterol, campesterol, and stigmasterol are shown in 
the appendix (p 4). Median percent changes in FGF-19 
were –13·9 (IQR –35·9 to 16·5) in the placebo 
group, –49·0 (–59·6 to –22·5) in the seladelpar 50 mg 
group, and –78·1 (–84·7 to –31·8) in the seladelpar 
Placebo group 
(n=13)
Seladelpar 50 mg 
group (n=13)
Seladelpar 200 mg 
group (n=12)
Age (years) 56 (48–61) 55 (49–58) 57 (54–65)
Sex
Female 12 (92%) 12 (92%) 12 (100%)
Male 1 (8%) 1 (8%) 0
Age at diagnosis (years) 52 (40–55) 49 (41–50) 43 (39–54)
Duration of primary biliary 
cholangitis (years)
4 (3–11) 7 (3–13) 9 (1–22)
Body-mass index (kg/m²) 28 (6) 24 (5) 27 (4)
Pruritus (visual analogue scale ≥30) 4 (33%) 4 (31%) 5 (50%)
Alkaline phosphatase (U/L)* 233 (73) 312 (95) 248 (89)
Alanine aminotransferase (U/L) 40 (24) 47 (31) 32 (15)
Aspartate aminotransferase (U/L) 36 (12) 37 (18) 32 (11)
γ-glutamyl transferase (U/L)* 183 (123) 220 (152) 104 (41)
Total bilirubin (mg/dL) 0·68 (0·35) 0·73 (0·27) 0·75 (0·38)
Albumin (g/dL) 4·3 (0·4) 4·3 (0·4) 4·1 (0·3)
Platelets (× 10³ per μL) 235 (83) 271 (86) 227 (79)
Total ursodeoxycholic acid dose 
(mg/kg per day)
16 (2) 15 (3) 14 (2)
Data are median (IQR), mean (SD), or n (%). *Data calculated on the efficacy population.
Table 1: Patient demographics and baseline characteristics
Week 0 Week 2 Week 4 Week 8 Week 12
Placebo 0/12 1/12 1/10 1/6 0/4
Seladelpar 50 mg 0/13 2/13 4/8 4/5 3/3
Seladelpar 200 mg 0/10 5/10 5/6 4/4 2/2
*Central laboratory upper limit of normal for alkaline phosphatase is 116 U/L.
Table 2: Number of patients with normalisation of alkaline phosphatase 
according to week(s) of treatment*
Figure 2: Mean percentage change in alkaline phosphatase over 12 weeks 
(last observation carried forward)
Bars are SD.
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200 mg group. These changes were significant versus 
placebo (p=0·047 for seladelpar 50 mg and p=0·006 for 
seladelpar 200 mg; appendix p 12).
There were no deaths during the study and no serious 
adverse events during the treatment period. Apart from 
the ALT events previously described, no adverse events 
were considered severe. The most frequently reported 
adverse events were pruritus (16%), nausea (13%), 
diarrhoea (10%) and dyspepsia, muscle spasms, 
myalgia, and dizziness (each 8%; table 3). There were 
no apparent differences in the distribution of adverse 
events between groups apart from the grouping of 
muscle-related adverse events (myalgia, muscle spasms, 
and musculoskeletal pain). All adverse evnets are shown 
in the appendix (pp 8, 9). Six muscle-related adverse 
events were recorded: one in the placebo group and five 
in the seladelpar 200 mg group (including a patient who 
discontinued for a muscle adverse event).
In total, five patients discontinued treatment before the 
study termination. Three of these were for the grade 3 
ALT increases that led to study closure (one patient on 
seladelpar 50 mg, two on seladelpar 200 mg). Two other 
patients in the seladelpar 200 mg group discontinued: 
one because of an increase in creatine associated with 
muscle pain discussed above, and one was lost to 
follow-up. 
All three grade 3 ALT elevations that led to 
discontinuation and study termination were judged 
probably drug related. ALT elevations were similar: 
rapid onset (identified during the first on-treatment visit 
at week 2), asymptomatic, and fully reversible 2–4 weeks 
after treatment discontinuation. There was no 
eosinophilia or concurrent elevation in total bilirubin. 
All ALT elevations were associated with decreases in 
GGT, as well as decreases in alkaline phosphatase 
(appendix p 13). Two additional patients developed 
grade 2 ALT elevations that did not lead to treatment 
interruption. Both patients were on seladelpar 200 mg 
(appendix p 6).
Pruritus was reported by one patient on placebo, 
four on seladelpar 50 mg, and one on seladelpar 
200 mg. Three pruritus adverse events were considered 
treatment related: one on placebo, two on seladelpar 
50 mg, and none on seladelpar 200 mg. 13 (34%) 
patients were considered to have pruritus at baseline 
(as judged with a pruritus visual analogue score ≥30): 
four on placebo, four on seladelpar 50 mg, and five on 
seladelpar 200 mg (table 1). At baseline, mean pruritus 
visual analogue scores were 18 (SD 18) in the placebo 
group, 21 (22) in the seladelpar 50 mg group, and 
33 (25) in the seladelpar 200 mg group. The mean 
visual analogue scores at end of treatment were 
27 (SD 27) in the placebo group, 21 (24) in the seladelpar 
50 mg group, and 31 (31) in the seladelpar 200 mg 
group. The 5D-itch mean total scores at baseline were 
11 (SD 4) in the placebo group, 11 (5) in the seladelpar 
50 mg group, and 11 (3) in the seladelpar 200 mg group. 
At the end of treatment, the 5D-itch mean total scores 
were 11 (SD 4) in the placebo group, 12 (6) in the 
seladelpar 50 mg group, and 11 (4) in the seladelpar 
200 mg group.
No relevant changes in haematology parameters were 
recorded. Mean percentage changes in haemoglobin, 
serum creatinine, and serum homocysteine are presented 
in the appendix (p 1).
Seladelpar plasma exposure data indicated that trough 
(pre-dose samples) concentrations did not appear 
higher than expected, notably for patients with grade 3 
aminotransferase elevation (appendix p 14).
Discussion
The objectives of this study were to evaluate the safety 
and efficacy of seladelpar to lower alkaline phosphatase 
concentrations in patients with primary biliary 
Figure 3: Mean changes in alkaline phosphatase over 12 weeks for each treatment group
ULN=upper limit of normal. LLN=lower limit of normal. Bars are SE.
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cholangitis showing an inadequate response to 
ursodeoxycholic acid. Seladelpar is the first potent and 
selective PPAR-δ agonist to be evaluated in primary 
biliary cholangitis and the key role played by PPAR-δ in 
the regulation of bile acid synthesis, inflammation and 
fibrosis, justified this objective. Seladelpar, originally 
developed to lower lipids in patients with mixed 
dyslipidaemia, was also previously associated with 
consistent decreases in markers of cholestasis, including 
alkaline phosphatase and GGT.12
The study used a dose-ranging, placebo-controlled, 
double-blind design that has been previously used in 
this setting, and applied similar eligibility criteria to 
facilitate comparison with obeticholic acid.28 Specifically, 
inadequate responders to ursodeoxycholic acid treat-
ment, according to accepted criteria, were enrolled and 
seladelpar was used as an add-on therapy. The study 
intended to exclude patients with decompensated 
cirrhosis but one random ised patient developed a 
variceal bleeding complication before receiving any 
treatment. It is known that some patients with primary 
biliary cholangitis can develop gastro-oesophageal 
varices before becoming cirrhotic.2
The study was discontinued when about half of the 
patients were enrolled as a result of three grade 3 
increases in ALT levels. The study was stopped to protect 
patients and because large decreases in GGT and 
5ʹ-nucleotidase indicated that the proof-of-concept for 
activity was likely to have been achieved. Additionally, 
new results from a rat disposition study revealed that 
seladelpar and its metabolites were almost exclusively 
eliminated through bile, which potentially suggested that 
higher than expected hepatic concentrations of seladelpar 
might have occurred in patients with primary biliary 
cholangitis (CymaBay Therapeutics, Newark, CA, USA; 
data not shown). However, seladelpar treatment, both at 
the 50 mg and 200 mg doses, elicited large percentage 
alkaline phosphatase decreases and normalised alkaline 
phosphatase in all five patients who completed 12 weeks 
of therapy.
The three cases of grade 3 ALT elevation that led to 
stopping the study were judged related to seladelpar and 
were clinically similar. There was a rapid onset of elevation 
on treatment initiation, a rapid return to baseline 
concentrations after drug interruption, and the increases 
were not associated with total bilirubin elevation or signs 
of idiosyncrasy, such as allergic reaction or eosinophilia. In 
each case, the aminotransferase elevations were associated 
with a parallel decrease in markers of cholestasis, such as 
alkaline phosphatase and GGT. Based on available data, 
there were no clinical or biological characteristics that 
could differentiate patients with aminotransferase 
elevation from the other patients. Examining all cases of 
ALT elevation during treatment, whether grade 2 or 
grade 3, there was a suggestion that ALT elevations were 
dose related, with more cases on seladelpar 200 mg.
The aminotransferase elevations were unexpected, as 
this was not reported in previous studies in which 
patients were treated with seladelpar for up to 12 weeks 
and with daily doses of up to 200 mg.12,26,27 Thus, this 
effect could be specific to primary biliary cholangitis 
and its underlying cholestasis. As mentioned, recent 
data in rats indicate that seladelpar and its metabolites 
are almost exclusively excreted into the bile (data not 
shown). Therefore, increased drug retention in primary 
biliary cholangitis could have led to higher liver 
concentrations in this study compared with studies in 
non-cholestatic patients. Seladelpar trough plasma 
concentrations did not suggest a higher exposure, either 
in patients with aminotransferase elevations relative to 
patients with no elevation, or in the patients with 
primary biliary cholangitis overall compared with other 
studies (data not shown). However, only a full 
pharmacokinetic profile would provide evidence to the 
hypothesis that seladelpar exposure was unexpectedly 
increased in patients with primary biliary cholangitis. 
We also would have to assume that plasma 
concentrations of seladelpar and its metabolites truly 
reflect their intra-hepatic concentrations. Alternatively, 
seladelpar or its metabolites might evoke an immune 
reaction in patients with primary biliary cholangitis that 
would not occur in patients who did not have primary 
biliary cholangitis. Concerning the specific mechanism 
of the observed aminotransferase elevations, there is 
currently no further information available to invoke 
one. Although an acute aminotransferase elevation is 
usually interpreted as a sign of hepatocyte cytolysis,29 it 
is also known that PPAR agonists can upregulate 
aminotransferase gene expression.30,31 Post-hoc analyses 
of stored samples evaluating more specific makers of 
liver injury32 is necessary to further explore this issue. 
Placebo group 
(n=13)
Seladelpar 50 mg 
group (n=13)
Seladelpar 200 mg 
group (n=12)
Grade 1–2 Grade 3 Grade 1–2 Grade 3 Grade 1–2 Grade 3
Pruritus 1 (8%) 0 4 (31%) 0 1 (8%) 0
Nausea 1 (8%) 0 3 (23%) 0 1 (8%) 0
Diarrhoea 2 (15%) 0 1 (8%) 0 1 (8%) 0
Dizziness 1 (8%) 0 2 (15%) 0 0 0
Dyspepsia 0 0 2 (15%) 0 1 (8%) 0
Muscle spasms 0 0 0 0 3 (25%) 0
Myalgia 1 (8%) 0 0 0 2 (17%) 0
Alanine aminotransferase 
increased
0 0 0 0 2 (17%) 0
Aspartate aminotransferase 
increased
0 0 0 0 1 (8%) 1 (8%)
Hepatic enzyme 
and aminotransferase 
increased
0 0 1 (8%) 1 (8%) 0 2 (17%)
Oropharyngeal pain 0 0 2 (15%) 0 0 0
No grade 4 or 5 adverse events occurred. 
Table 3: Common Terminology Criteria adverse event categories occurring in two or more individuals 
per group
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Animal studies could be useful to determine the 
relationship between hepatic and plasma concentrations 
of seladelpar. In this study, the concentrations of 
chenodeoxycholic acid or lithocholic acid, which have 
been associated with hepatotoxicity,33 were not increased 
compared with baseline, making this mechanism of 
action unlikely.
Seladelpar did not appear to be associated with drug-
induced or worsened pruritus. This feature might, if 
replicated, differentiate seladelpar from obeticholic acid, 
as the tolerability of obeticholic acid is limited by this 
side-effect.4 However, the size of the current study 
precludes any conclusion on whether seladelpar might 
have a beneficial effect on pruritus of primary biliary 
cholangitis, as has been suggested for bezafibrate.34
With regard to other safety parameters, at the 200 mg 
dose of seladelpar one patient discontinued treatment 
with muscle pain and increased creatine kinase 
concentration that were considered treatment related. By 
contrast with other PPARs, the δ receptor is expressed in 
muscle. Although such adverse events were not observed 
with seladelpar when prescribed in patients with 
homozygous familial hypercholesterolaemia on 
maximally tolerated statin therapy,27 caution should 
be exercised. Seladelpar was also associated with 
dose-dependent elevations of serum homocysteine and 
serum creatinine concentrations, which are commonly 
observed with other PPARs.35–37 The increase in serum 
creatinine could be problematic because it is used 
clinically as a marker of decreased renal glomerular 
filtration and the glomerular filtration rate is estimated 
with a formula that is based on serum creatinine 
concentrations.38 One patient had an increase in serum 
creatinine that was considered clinically significant by 
the investigator. Previous studies have shown that 
increased serum creatinine associated with some PPAR 
agonists, such as PPAR-α, pan-PPAR, or mixed 
PPAR-α/δ, was neither linked to relevant decrease in 
measured glomerular filtration rate nor to changes 
in measured creatinine clearance, because serum 
creatinine and creatinine urinary excretion increased in 
similar proportions.39 Long-term prospective studies of 
fenofibrate, a PPAR-α agonist, in patients with diabetes 
with compromised renal function, did not show a 
negative effect on renal function, despite small increases 
in serum creatinine.40 Finally, increases in serum 
creatinine associated with PPARs, as seen in the current 
study, are reversible,41 which rules out permanent kidney 
damage. The PPAR-mediated increase in serum 
creatinine has been postulated to result from an 
increased release of creatine from muscle. Creatine is 
stored in muscles to supply energy and is rapidly 
converted to creatinine in the serum.42
All five patients who received seladelpar for 12 weeks 
normalised their alkaline phosphatase concentrations. 
This activity in patients who are inadequate responders 
to ursodeoxycholic acid appears greater than that seen 
with obeticholic acid in a similarly designed phase 2 
study.28 By contrast with the aminotransferase elevations, 
seladelpar’s activity was not dose related, and the effect 
seemed already maximal at 50 mg, which calls for the 
exploration of lower doses to optimise the risk–benefit 
ratio of the drug. The decrease in alkaline phosphatase 
was also associated with decreases in other markers of 
cholestasis, including GGT and 5ʹ-nucleotidase, and the 
50 mg dose of seladelpar was also associated with 
decreases in total bilirubin concentrations. Similar to 
ursodeoxycholic acid and obeticholic acid,2,28 the 
concentrations of markers of cholestatic injury returned 
to baseline concentrations when seladelpar treatment 
was stopped.
The study has some important limitations. Because the 
study was discontinued before its completion and because 
of its small sample size, these data are preliminary and 
should be confirmed in larger studies. The conclusion 
regarding alkaline phosphatase normalisation is only 
based on five patients who have reached 12 weeks of 
treatment, and the aminotransferase elevation was 
concerning enough to terminate the study. Nevertheless, 
the normalisation of alkaline phosphatase with seladelpar, 
if confirmed at lower doses in the absence of a safety 
signal, offers promise for a new treatment approach in 
patients with primary biliary cholangitis who do not 
respond fully to ursodeoxycholic acid therapy.
This study provides evidence regarding the mechanism 
of action of seladelpar. First, there was a striking effect on 
hepatocyte bile acids synthesis as shown by a decrease in 
serum C4 concentrations, a reliable marker of the activity 
of 7α-hydroxylase which hydroxylates cholesterol in 
position 7 and constitutes the rate-limiting step in bile 
acids synthesis by the classical pathway.43 The decrease in 
C4 concentrations was not meaningfully different 
between the two seladelpar doses. The C4 data were 
corroborated by a decrease in 7α-hydroxy-cholesterol and 
by decreases in cholic acid concentrations, the product of 
the classic pathway, and further by decreases in 
deoxycholic acid, a metabolite of cholic acid.44 Additional 
reductions in hepatic bile acids might have resulted from 
decreases in cholesterol absorption and decreases in 
cholesterol synthesis intermediates. Overall, these data 
suggest that seladelpar can reduce bile acid concentrations 
by decreasing their synthesis as well as decreasing the 
availability of cholesterol as a substrate for their synthesis. 
Treatment with ursodeoxycholic acid increases transport 
of bile acids into the canalicular space, which is believed 
to be hepatoprotective due to the lowering of bile acid 
concentrations within hepatocytes.45 Seladelpar’s 
inhibition of bile acid metabolism might therefore 
potentiate this beneficial effect by further lowering 
hepatocyte concentrations of bile acids. Additionally, 
seladelpar-induced decreases in hs-CRP are consistent 
with anti-inflammatory activity of the drug, an action 
first demonstrated in patients with obesity and mixed 
dyslipidaemia.12 Finally, the decreases in FGF-19 
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concentrations seen with seladelpar indicate that its 
action is not mediated through farnesoid X receptor 
agonism as is the case for obeticholic acid.4 It has also 
been suggested that FGF-19 might play a role in the 
development of hepatocellular carcinoma and that its 
expression is induced in the liver under cholestatic and 
cirrhotic conditions.46 As in the case with other chronic 
liver diseases, patients with primary biliary cholangitis 
are at an increased risk of hepatocellular carcinoma,1,2 
and the decreased concentrations of FGF-19 induced by 
seladelpar could be of interest.
In conclusion, this study demonstrated that seladelpar, 
at both the 50 mg and 200 mg daily doses, has 
the potential to normalise biochemical markers of 
cholestasis in patients with primary biliary cholangitis 
who have inadequately responded to ursodeoxycholic 
acid. However, treatment with seladelpar was associated 
with aminotransferase elevations and, consequently, the 
study was interrupted before completion. Since the 
elevation of aminotransferases was more frequent at 
200 mg com pared with 50 mg, while the anti-cholestatic 
activity was independent of doses, lower doses 
of seladelpar should be explored to optimise the 
risk–benefit ratio in patients with primary biliary 
cholangitis. A study of low-dose seladelpar in patients 
with primary biliary cholangitis has been initiated 
(NCT02955602 and EudraCT 2016-002996-91).
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